MA50093B1 - Composé pentacyclique - Google Patents
Composé pentacycliqueInfo
- Publication number
- MA50093B1 MA50093B1 MA50093A MA50093A MA50093B1 MA 50093 B1 MA50093 B1 MA 50093B1 MA 50093 A MA50093 A MA 50093A MA 50093 A MA50093 A MA 50093A MA 50093 B1 MA50093 B1 MA 50093B1
- Authority
- MA
- Morocco
- Prior art keywords
- pentacyclic compound
- pentacyclic
- compound
- formulas
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne des composés représentés par les formules (i) à (vi) ou des sels pharmaceutiquement acceptables de ceux-ci :
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017172169 | 2017-09-07 | ||
| PCT/JP2018/032797 WO2019049869A1 (fr) | 2017-09-07 | 2018-09-05 | Composé pentacyclique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50093A MA50093A (fr) | 2021-05-05 |
| MA50093B1 true MA50093B1 (fr) | 2022-05-31 |
Family
ID=65517037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50093A MA50093B1 (fr) | 2017-09-07 | 2018-09-05 | Composé pentacyclique |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US10239889B1 (fr) |
| EP (1) | EP3680243B1 (fr) |
| JP (1) | JP6557441B1 (fr) |
| KR (1) | KR102307738B1 (fr) |
| CN (1) | CN111051316B (fr) |
| AR (1) | AR112788A1 (fr) |
| AU (1) | AU2018330578B2 (fr) |
| BR (1) | BR112020003197A2 (fr) |
| CA (1) | CA3072740A1 (fr) |
| CL (1) | CL2020000376A1 (fr) |
| CO (1) | CO2020001471A2 (fr) |
| CY (1) | CY1125355T1 (fr) |
| DK (1) | DK3680243T3 (fr) |
| ES (1) | ES2903172T3 (fr) |
| HR (1) | HRP20220019T1 (fr) |
| HU (1) | HUE056791T2 (fr) |
| IL (1) | IL272652B (fr) |
| JO (1) | JOP20200030A1 (fr) |
| LT (1) | LT3680243T (fr) |
| MA (1) | MA50093B1 (fr) |
| MD (1) | MD3680243T2 (fr) |
| MX (1) | MX2020001786A (fr) |
| PE (1) | PE20200860A1 (fr) |
| PH (1) | PH12020500341A1 (fr) |
| PL (1) | PL3680243T3 (fr) |
| PT (1) | PT3680243T (fr) |
| RS (1) | RS62796B1 (fr) |
| RU (1) | RU2754557C1 (fr) |
| SG (1) | SG11202001240XA (fr) |
| SI (1) | SI3680243T1 (fr) |
| SM (1) | SMT202200004T1 (fr) |
| TW (1) | TWI707859B (fr) |
| UA (1) | UA125940C2 (fr) |
| WO (1) | WO2019049869A1 (fr) |
| ZA (2) | ZA202000970B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020003494A2 (pt) | 2017-09-07 | 2020-08-25 | Augusta University Research Institute, Inc | composto, métodos para aumentar uma resposta imunossupressora, para tratar um distúrbio inflamatório, uma doença autoimune, doença do enxerto contra hospedeiro, infecção crônica e obesidade e para inibir ou reduzir a rejeição a um transplante, e, composição farmacêutica |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| IL285511B2 (en) | 2019-03-05 | 2024-10-01 | Eisai R&D Man Co Ltd | Pentacyclic heterocyclic compounds and pharmaceutical compositions comprising them for the treatment of cognitive dysfunction |
| TWI849070B (zh) * | 2019-03-05 | 2024-07-21 | 日商衛材R&D企管股份有限公司 | 五環化合物之鹽及其等之結晶 |
| US20230101747A1 (en) * | 2019-12-06 | 2023-03-30 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187306A (en) * | 1977-07-26 | 1980-02-05 | Bayer Aktiengesellschaft | Benzodiazepine-diones, a process for their production and their use as medicaments |
| DD258234A1 (de) * | 1987-03-05 | 1988-07-13 | Univ Leipzig | Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine |
| RU2117670C1 (ru) * | 1988-10-31 | 1998-08-20 | Эйсай Ко., Лтд. | Производные триазоло[1,4]диазепина и способы их получения |
| TW197442B (fr) * | 1990-02-08 | 1993-01-01 | Pfizer | |
| KR100203456B1 (ko) * | 1995-06-20 | 1999-06-15 | 한승수 | 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제 |
| FR2779652B1 (fr) * | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| WO2006045429A1 (fr) * | 2004-10-20 | 2006-05-04 | F. Hoffmann-La Roche Ag | Dérivés de benzodiazépine à substitution halogène |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
-
2018
- 2018-09-05 AR ARP180102517A patent/AR112788A1/es active IP Right Grant
- 2018-09-05 JO JOP/2020/0030A patent/JOP20200030A1/ar unknown
- 2018-09-05 ES ES18853415T patent/ES2903172T3/es active Active
- 2018-09-05 MD MDE20200725T patent/MD3680243T2/ro unknown
- 2018-09-05 DK DK18853415.0T patent/DK3680243T3/da active
- 2018-09-05 UA UAA202000934A patent/UA125940C2/uk unknown
- 2018-09-05 RU RU2020106798A patent/RU2754557C1/ru active
- 2018-09-05 SG SG11202001240XA patent/SG11202001240XA/en unknown
- 2018-09-05 WO PCT/JP2018/032797 patent/WO2019049869A1/fr not_active Ceased
- 2018-09-05 CN CN201880053052.1A patent/CN111051316B/zh active Active
- 2018-09-05 PT PT188534150T patent/PT3680243T/pt unknown
- 2018-09-05 HU HUE18853415A patent/HUE056791T2/hu unknown
- 2018-09-05 PL PL18853415T patent/PL3680243T3/pl unknown
- 2018-09-05 US US16/122,116 patent/US10239889B1/en active Active
- 2018-09-05 PE PE2020000228A patent/PE20200860A1/es unknown
- 2018-09-05 HR HRP20220019TT patent/HRP20220019T1/hr unknown
- 2018-09-05 MA MA50093A patent/MA50093B1/fr unknown
- 2018-09-05 SI SI201830467T patent/SI3680243T1/sl unknown
- 2018-09-05 JP JP2019516726A patent/JP6557441B1/ja active Active
- 2018-09-05 LT LTEPPCT/JP2018/032797T patent/LT3680243T/lt unknown
- 2018-09-05 EP EP18853415.0A patent/EP3680243B1/fr active Active
- 2018-09-05 MX MX2020001786A patent/MX2020001786A/es unknown
- 2018-09-05 TW TW107131095A patent/TWI707859B/zh active
- 2018-09-05 KR KR1020207004232A patent/KR102307738B1/ko active Active
- 2018-09-05 RS RS20220015A patent/RS62796B1/sr unknown
- 2018-09-05 AU AU2018330578A patent/AU2018330578B2/en active Active
- 2018-09-05 SM SM20220004T patent/SMT202200004T1/it unknown
- 2018-09-05 CA CA3072740A patent/CA3072740A1/fr active Pending
- 2018-09-05 BR BR112020003197-6A patent/BR112020003197A2/pt active IP Right Grant
- 2018-09-05 IL IL272652A patent/IL272652B/en unknown
-
2020
- 2020-02-11 CO CONC2020/0001471A patent/CO2020001471A2/es unknown
- 2020-02-13 CL CL2020000376A patent/CL2020000376A1/es unknown
- 2020-02-14 ZA ZA2020/00970A patent/ZA202000970B/en unknown
- 2020-02-14 PH PH12020500341A patent/PH12020500341A1/en unknown
- 2020-12-11 ZA ZA2020/07737A patent/ZA202007737B/en unknown
-
2022
- 2022-01-10 CY CY20221100025T patent/CY1125355T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
| MA50093B1 (fr) | Composé pentacyclique | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| PH12020551013A1 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| BR112017019286A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável deste | |
| PH12020550993A1 (en) | Amino-methyl piperidine derivative as kinase inhibitor | |
| EA201792021A1 (ru) | Ингибитор jak | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MA46337A (fr) | Composé de pyridine | |
| MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
| MA44781B1 (fr) | Composé hétérocyclique condensé | |
| JO3742B1 (ar) | مركب بيرانو داي بيريدين | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| CU20200035A7 (es) | Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2 | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| MA38991A1 (fr) | Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt |